---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-102446"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-08-27T20:11:23+00:00"
generated_at: "2026-08-27T20:12:14.430362+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics names Kevin Lundquist CFO, Kenyon departs Sept 1

## Summary
- CFO Lawrence Kenyon to step down Sept 1, 2026; stays non-executive through Sept 30, 2026; leaves board by then.
- Kevin Lundquist appointed CFO, Treasurer, principal financial/accounting officer effective Sept 1; previously CFO at CapsoVision (Nasdaq: CV).
- Lundquist receives $450k base salary, 50% target bonus, and option for 500k shares vesting over 4 years.
- Kenyon severance: 12 months base salary + $20k + full 2026 target bonus; 100% option acceleration; 12 months COBRA.
- Board to shrink to eight directors upon Kenyon's board departure; transition not due to any accounting or policy disagreement.

## SEC filing metadata
- accession: 0001104659-26-102446
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-08-27T20:11:23+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926102446/0001104659-26-102446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926102446/tm2624167d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-102446
- JSON: https://secwatch.observer/filing/0001104659-26-102446.json
- Plain text: https://secwatch.observer/filing/0001104659-26-102446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.